Analysts Set Expectations for ADMA Biologics FY2025 Earnings

ADMA Biologics Inc (NASDAQ:ADMA - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of ADMA Biologics in a research note issued on Wednesday, June 25th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of $0.61 for the year, down from their prior estimate of $0.72. Cantor Fitzgerald currently has a "Overweight" rating and a $25.00 target price on the stock. The consensus estimate for ADMA Biologics' current full-year earnings is $0.51 per share. Cantor Fitzgerald also issued estimates for ADMA Biologics' FY2026 earnings at $0.89 EPS.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same quarter in the previous year, the business posted $0.08 earnings per share. The company's quarterly revenue was up 40.2% compared to the same quarter last year.

A number of other research firms also recently issued reports on ADMA. Raymond James Financial raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock traded down $0.24 during trading hours on Thursday, reaching $18.16. The company's stock had a trading volume of 4,944,670 shares, compared to its average volume of 3,698,999. The company's 50 day simple moving average is $20.57 and its 200 day simple moving average is $18.74. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. ADMA Biologics has a one year low of $10.21 and a one year high of $25.67. The stock has a market cap of $4.34 billion, a P/E ratio of 21.36 and a beta of 0.47.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock worth $312,109,000 after buying an additional 80,302 shares in the last quarter. Invesco Ltd. raised its position in shares of ADMA Biologics by 13.9% during the 1st quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after buying an additional 1,570,649 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ADMA Biologics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock worth $93,187,000 after buying an additional 50,399 shares in the last quarter. Nuveen LLC bought a new stake in shares of ADMA Biologics during the 1st quarter worth about $93,543,000. Finally, Dimensional Fund Advisors LP raised its position in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after buying an additional 643,661 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 137,931 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $20.82, for a total transaction of $2,871,723.42. Following the sale, the director now directly owns 282,079 shares in the company, valued at approximately $5,872,884.78. The trade was a 32.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence P. Guiheen sold 7,779 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total transaction of $158,069.28. Following the sale, the director now owns 114,830 shares in the company, valued at $2,333,345.60. This trade represents a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock worth $9,644,269 in the last ninety days. 3.70% of the stock is owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.